Literature DB >> 28479512

Long-term prognosis of drug-induced Brugada syndrome.

Juan Sieira1, Giuseppe Ciconte2, Giulio Conte2, Carlo de Asmundis2, Gian-Battista Chierchia2, Giannis Baltogiannis2, Giacomo Di Giovanni2, Yukio Saitoh2, Ruben Casado-Arroyo2, Justo Juliá2, Mark La Meir3, Francis Wellens3, Kristel Wauters2, Gudrun Pappaert2, Pedro Brugada2.   

Abstract

BACKGROUND: Patients with drug-induced Brugada syndrome (BS) are considered at a lower risk than those with a spontaneous type I pattern. Nevertheless, they can present arrhythmic events.
OBJECTIVE: The purpose of this study was to investigate their clinical characteristics, long-term prognosis and risk factors.
METHODS: A consecutive cohort of 343 patients with drug-induced BS was included and compared with 78 patients with a spontaneous type I pattern.
RESULTS: The mean age was 40.7 ± 18.3 years. Sudden cardiac death (SCD) was the clinical presentation in 13 (3.8%) and syncope in 86 (25.1%); 244 (71.1%) were asymptomatic. Patients with drug-induced BS were less frequently men (180 (52.5%) vs 63 (80.8%); P < .01), were more frequently asymptomatic (244 (71.1%) vs 44 (56.4%); P < .01), and had less ventricular arrhythmias (VAs) induced during electrophysiology study (41 (13.2%) vs 31 (42.4%); P < .01). An implantable cardioverter-defibrillator was implanted in 128 patients (37.3%). During a median follow-up of 62.5 months (interquartile range 28.9-115.6 months), 34 patients presented arrhythmic events. The event rate was 1.1% person-year (vs 2.3% person-year in patients with a spontaneous type I pattern; P < .01). Presentation as SCD and inducible VAs were independent risk factors significantly associated with arrhythmic events (adjusted hazard ratio 22.0 and 3.5). Drug-induced BS was related to a better prognosis only in asymptomatic individuals.
CONCLUSION: Drug-induced BS has a good prognosis if asymptomatic; however, SCD is possible. Clinical presentation as SCD and inducible VAs during electrophysiology study are independent risk factors for arrhythmic events. In asymptomatic patients, proband status and inducible VAs can help to identify patients at higher risk, but further evidence is needed.
Copyright © 2017 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brugada syndrome; Clinical characterization; Implantable cardioverter-defibrillator; Prognosis; Risk stratification; Sudden cardiac death

Mesh:

Substances:

Year:  2017        PMID: 28479512     DOI: 10.1016/j.hrthm.2017.04.044

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  5 in total

Review 1.  Electrophysiological Basis for Early Repolarization Syndrome.

Authors:  Rubén Casado Arroyo; Juan Sieira; Maciej Kubala; Decebal Gabriel Latcu; Shigo Maeda; Pedro Brugada
Journal:  Front Cardiovasc Med       Date:  2018-11-06

2.  Evaluating the Use of Genetics in Brugada Syndrome Risk Stratification.

Authors:  Michelle M Monasky; Emanuele Micaglio; Emanuela T Locati; Carlo Pappone
Journal:  Front Cardiovasc Med       Date:  2021-04-21

3.  Prognostic Significance of the Sodium Channel Blocker Test in Patients With Brugada Syndrome.

Authors:  Akira Ueoka; Hiroshi Morita; Atsuyuki Watanabe; Yoshimasa Morimoto; Satoshi Kawada; Motomi Tachibana; Masakazu Miyamoto; Koji Nakagawa; Nobuhiro Nishii; Hiroshi Ito
Journal:  J Am Heart Assoc       Date:  2018-05-10       Impact factor: 5.501

4.  Outcomes in Brugada Syndrome Patients With Implantable Cardioverter-Defibrillators: Insights From the SGLT2 Registry.

Authors:  Sharen Lee; Ka Hou Christien Li; Jiandong Zhou; Keith Sai Kit Leung; Rachel Wing Chuen Lai; Guoliang Li; Tong Liu; Konstantinos P Letsas; Ngai Shing Mok; Qingpeng Zhang; Gary Tse
Journal:  Front Physiol       Date:  2020-03-10       Impact factor: 4.566

Review 5.  Role of Provocable Brugada ECG Pattern in The Correct Risk Stratification for Major Arrhythmic Events.

Authors:  Nicolò Martini; Martina Testolina; Gian Luca Toffanin; Rocco Arancio; Luca De Mattia; Sergio Cannas; Giovanni Morani; Bortolo Martini
Journal:  J Clin Med       Date:  2021-03-02       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.